Stock Analysis on Net

Allergan PLC (NYSE:AGN)

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Common-Size Income Statement
Quarterly Data

Allergan PLC, common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Net revenues 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost of sales, excludes amortization and impairment of acquired intangibles including product rights -17.29 -16.18 -15.78 -15.95 -13.84 -14.46 -15.26 -11.68 -14.24 -13.43 -14.54 -13.73 -12.61 -12.41 -12.76 -11.98 -14.04 -15.66 -30.40 -37.01 -39.81
Gross profit 82.71% 83.82% 84.22% 84.05% 86.16% 85.54% 84.74% 88.32% 85.76% 86.57% 85.46% 86.27% 87.39% 87.59% 87.24% 88.02% 85.96% 84.34% 69.60% 62.99% 60.19%
Research and development -11.93 -10.40 -11.71 -11.00 -12.09 -16.62 -10.85 -16.71 -12.93 -9.44 -10.97 -12.21 -21.27 -23.63 -17.19 -17.27 -11.86 -12.21 -30.83 -7.90 -12.40
Selling and marketing -26.97 -20.29 -22.25 -21.35 -22.35 -20.63 -19.32 -20.69 -21.79 -20.29 -20.64 -23.34 -24.32 -21.65 -21.98 -23.52 -22.56 -24.08 -17.65 -17.05 -22.23
General and administrative -11.13 -17.39 -26.98 -7.93 -8.57 -8.63 -7.39 -8.10 -8.06 -8.99 -8.35 -11.47 -8.85 -11.39 -9.97 -9.31 -9.69 -14.77 -8.59 -8.34 -21.09
Amortization -39.30 -34.88 -37.96 -34.28 -38.90 -38.46 -40.61 -41.15 -46.23 -44.43 -44.15 -43.87 -48.59 -42.40 -44.42 -44.32 -46.77 -53.74 -38.16 -29.08 -30.74
Goodwill impairments -25.33 0.00 0.00 -26.55 -68.58 -69.64 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
In-process research and development impairments 0.00 0.00 0.00 -10.66 0.00 -0.16 0.00 -6.69 -14.22 -4.78 -5.01 -17.55 -9.52 -11.05 -1.16 -7.30 -0.18 -0.53 -7.34 -3.43 0.00
Asset sales and impairments, net -4.11 -7.22 -0.05 -3.16 0.14 -63.37 0.01 -6.29 -0.36 -0.73 -96.05 -0.35 -0.21 -0.75 0.13 0.48 0.05 -10.18 0.11 -0.01 -0.18
Operating income (loss) -36.06% -6.36% -14.73% -30.88% -64.20% -131.97% 6.58% -11.32% -17.81% -2.09% -99.70% -22.52% -25.36% -23.29% -7.35% -13.23% -5.05% -31.17% -32.86% -2.83% -26.45%
Interest income 0.59 0.58 0.51 0.24 0.59 0.28 0.26 0.15 0.47 0.34 0.28 0.41 0.71 1.20 0.50 0.07 0.09 0.12 0.09 0.05 0.07
Interest expense -5.12 -4.41 -4.79 -4.78 -5.61 -5.15 -5.63 -5.58 -6.82 -6.09 -6.57 -6.92 -8.11 -7.57 -8.95 -9.38 -9.79 -12.81 -8.32 -5.91 -6.71
Other income (expense), net -0.69 0.49 0.06 -0.11 0.38 -0.24 3.32 5.22 -2.15 -1.63 -32.48 -3.33 -53.82 0.91 0.93 4.07 0.01 0.47 0.00 -0.85 -7.72
Other income (expense), net -5.22% -3.34% -4.22% -4.66% -4.63% -5.11% -2.06% -0.20% -8.50% -7.38% -38.78% -9.84% -61.22% -5.47% -7.53% -5.24% -9.69% -12.22% -8.22% -6.71% -14.36%
Income (loss) before income taxes and noncontrolling interest -41.28% -9.70% -18.95% -35.53% -68.83% -137.08% 4.53% -11.52% -26.31% -9.47% -138.48% -32.36% -86.57% -28.76% -14.88% -18.48% -14.74% -43.38% -41.08% -9.54% -40.81%
(Provision) benefit for income taxes 51.79 2.41 -0.45 -7.37 1.91 31.78 -5.46 0.13 18.58 90.57 40.62 14.50 14.89 27.72 4.39 7.01 12.02 6.41 20.17 5.34 10.11
Net income (loss) from continuing operations, net of tax 10.51% -7.29% -19.39% -42.91% -66.92% -105.30% -0.93% -11.40% -7.73% 81.10% -97.86% -17.85% -71.68% -1.04% -10.49% -11.47% -2.71% -36.98% -20.91% -4.20% -30.70%
Income (loss) from discontinued operations, net of tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -8.91 -0.15 -0.21 -0.09 1.07 430.73 -2.10 10.26 13.36 150.59 0.00 10.71
Net income (loss) 10.51% -7.29% -19.39% -42.91% -66.92% -105.30% -0.93% -11.40% -7.73% 72.19% -98.01% -18.06% -71.77% 0.03% 420.24% -13.57% 7.54% -23.62% 129.68% -4.20% -19.99%
(Income) loss attributable to noncontrolling interest -0.03 0.00 -0.03 -0.10 -0.02 -0.10 -0.04 -0.06 -0.06 -0.04 -0.04 -0.05 -0.03 -0.05 -0.05 -0.05 -0.02 -0.06 -0.03 -0.03 0.01
Net income (loss) attributable to shareholders 10.49% -7.29% -19.42% -43.01% -66.94% -105.40% -0.97% -11.46% -7.79% 72.15% -98.05% -18.11% -71.80% -0.02% 420.19% -13.62% 7.52% -23.68% 129.65% -4.22% -19.98%
Dividends on preferred shares 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.26 -1.61 -1.73 -1.74 -1.95 -1.80 -1.92 -1.89 -2.05 -2.61 -1.70 -1.21 -0.91
Net income (loss) attributable to ordinary shareholders 10.49% -7.29% -19.42% -43.01% -66.94% -105.40% -0.97% -11.46% -9.05% 70.54% -99.78% -19.85% -73.74% -1.82% 418.27% -15.50% 5.47% -26.29% 127.95% -5.43% -20.89%

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

Income statement item Description The company
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Allergan PLC operating income (loss) as a percentage of net revenues increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Income (loss) before income taxes and noncontrolling interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Allergan PLC income (loss) before income taxes and noncontrolling interest as a percentage of net revenues increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Net income (loss) attributable to shareholders The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Allergan PLC net income (loss) attributable to shareholders as a percentage of net revenues increased from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.